Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials

Canadian Journal of Cardiology

Volumn 25, Issue 2, 2009, Pages 85-105

  Howlett, Jonathan G ^a   McKelvie, Robert S ^b   Arnold, J Malcolm O ^c   Costigan, Jeannine ^d   Dorian, Paul ^e   Ducharme, Anique ^f   Estrella Holder, Estrellita ^g   Ezekowitz, Justin A ^h   Giannetti, Nadia ⁱ   Haddad, Haissam ^j   Heckman, George A ^b   Herd, Anthony M ^k   Isaac, Debra ^a   Jong, Philip ^e   Kouz, Simon ^l   Liu, Peter ^e   Mann, Elizabeth ^m   Moe, Gordon W ⁿ   Tsuyuki, Ross T ^h   Ross, Heather J ^e   White, Michel ^f   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d St Mary's General Hospital   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g ST BONIFACE GENERAL HOSPITAL   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^k UNIVERSITY OF MANITOBA   (Canada)

^l Centre Hospitalier Regional de Lanaudiere   (Canada)

^m QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

Congenital heart disease; Consensus statement; Device therapy; Diagnosis; Drug therapy; Etiology; Guidelines; Heart failure; Myocarditis; Prognosis; Pulmonary hypertension; Right sided heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ILOPROST; LEVOSIMENDAN; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; PROSTACYCLIN; RAMIPRIL; ROSIGLITAZONE; SILDENAFIL; SOTALOL; TELMISARTAN; TEZOSENTAN; TOLVAPTAN; TROPONIN; UNINDEXED DRUG; UNIPROST; VALSARTAN; WARFARIN;

ANEMIA; ANGIOCARDIOGRAPHY; CANADA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONGENITAL HEART DISEASE; CONSENSUS DEVELOPMENT; CONSTRICTIVE PERICARDITIS; CONTINUOUS HEMOFILTRATION; COR PULMONALE; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE DYSPLASIA; HEART RIGHT VENTRICLE INFARCTION; HEART TRANSPLANTATION; HEART VALVE REPLACEMENT; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG SCINTISCANNING; MEDICAL SOCIETY; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT REFERRAL; PERICARDIAL DISEASE; PERICARDIECTOMY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RADIOFREQUENCY ABLATION; RESTRICTIVE CARDIOMYOPATHY; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; UREMIA; VALVULAR HEART DISEASE; ACUTE DISEASE; ARTICLE; HEART RIGHT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; RISK FACTOR;

ACUTE DISEASE; CANADA; CLINICAL TRIALS AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HEART FAILURE; HUMANS; MYOCARDITIS; RISK FACTORS; SOCIETIES, MEDICAL; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 63049116607     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70477-5     Document Type: Conference Paper

References (139)

1. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol 2006;22:23-45.
2. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007;23:21-45.
3. Arnold M, Howlett JG, Ducharme A, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure - 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol 2008;24:21-40.
4. Haddad F, Doyle R, Murphy QJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: Pathophysiology, clinical importance, and management of right ventricutar failure. Circulation 2008;117:1717-31.
5. Haddad F, Hunt SA, Rosenthal DN, Murphy QJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008;117:1436-48.
6. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114:1883-91.
7. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A repoft of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:210-47.
8. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension, pulmonary embolism: Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28.
9. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease) developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;52:1890-947.
10. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-802.
11. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736-54.
12. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by die Infectious Diseases Society of America. Circulation 2005;111:e394-e434.
13. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest 2005;127:1647-53.
14. Freitas D, Athanazio R, Almeida D, Dantas N, Reis F. Sildenafil improves quality of life in men with heart failure and erectile dysfunction. Int J Impot Res 2006;18:210-2.
15. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-62.
16. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
17. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implarivable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-23.
18. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol 2007;30(Suppl 1):S23-30.
19. Erdinler I, Okmen E, Turek O, et al. Tricuspid valve perforation by permanent pacemaker lead - a case report. Angiology 2005;56:619-21.
20. Heaven DJ, Henein MY, Sutton R. Pacemaker lead related tricuspid stenosis: A report of tivo cases. Heart 2000;83:351-2.
21. Huddleston CB, Rosenbloom M, Goldstein JA, Pasque MK. Biopsy-induced tricuspid regurgitation after cardiac transplantation. Ann Thorac Surg 1994;57:832-6; discussion 6-7.
22. Jaoude SA, Leclercq JF, Cournel P. Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease. Eur Heart J 1996;17:1717-22.
23. Peters S, Trummel M, Meyners W Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. Int J Cardiol 2004;97:499-501.
24. Moric-Janiszewska E, Markiewicz-Loskot G. Review on the genetics of arrhythmogenic right ventricular dysplasia. Europace 2007;9:259-66.
25. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994;71:215-8.
26. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Circulation 2004;110:1879-84.
27. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: A United States experience. Circulation 2005;112:3823-32.
28. Sen-Chowdhry S, Prasad SK, Syrris F, et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: Comparison with task force criteria and genotype. J Am Coll Cardiol 2006;48:2132,40.
29. Midiri M, Finazzo M, Brancato M, et al. Arrhythmogenic right ventricular dysplasia: MR features. Eur Radiol 1997;7:307-12.
30. Yoerger DM, Marcus F, Sherrill D, et al. Echocardiographic. findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: New insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol 2005;45:860-5.
31. Angelini A, Thiene O, Boffa GM, et al. Endomyocardial biopsy in right ventricular cardiomyopathy. Int J Cardiol 1993;40:273-82.
32. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115:1710-20.
33. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108:3084-91.
34. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia. Devices): Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons, Circulation 2008;117:e350-e408.
35. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86:29-37.
36. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhydimogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007;50:432-40.
37. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Circulation 2004;110:1879-84.
38. Bauce B, Nava A, Rampazzo A, et al. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 2000;85:573-9.
39. Hodgkinson KA, Parfrey PS, Bassett AS, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 2005;45:400-8.
40. Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:974-80.
41. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. 36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocardids, and Marfan syndrome. J Am Coll Cardiol 2005;45:1340-5.
42. Mitchell JH, Haskell W, Snell P, Van Camp SR 36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities Task Force 8: Classification of sports. J Am Coll Cardiol 2005;45:1364-7.
43. Talreja DR, Edwards WD, Danielson GK, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 2003;108:1852-7.
44. Bergman M, Vitrai J, Salman H. Constrictive pericarditis: A reminder of a not so rare disease. Eur J Intern Med 2006;17:457-64.
45. Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J 1987;113:354-60.
46. Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary: The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004;25:587-610.
47. Wang ZJ, Reddy GP, Gotway MB, Yeh BM, Hetts SW, Higgins CB. CT and MR imaging of pericardial disease. Radiographics 2003;23(Suppl):S167-S180.
48. Vaitkus PT, Kussmaul WG. Constrictive pericarditis versus restrictive cardiomyopathy: A reappraisal and update of diagnostic criteria. Am Heart J 1991;122:1431-41.
49. Hurrell DG, Nishimura RA, Higano ST, et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation 1996;93:2007-13.
50. Talreja DR, Nishimura RA, Oh JK, Holmes DR. Constrictive pericarditis in the modern era: Novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll Cardiol 2008;51:315-9.
51. Rajagopalan N, Garcia MJ, Rodriguez L, et al. Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 2001;87:86-94.
52. Babuin L, Alegria JR, Oh JK, Nishimura RA, Jaffe AS. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. J Am Coll Cardiol 2006;47:1489-91.
53. Goldstein JA. Cardiac tamponade, constrictive pericarditis, and restrictive cardiomyopathy. Curr Probl Cardiol 2004;29:503-67.
54. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987;2:1418-22.
55. Ansinelli RA, Weeks KD, Key TS. Effect of steroids on postoperative constrictive pericarditis. Am J Cardiol 1983;51:1238-40.
56. Yetkin U, Kestelli M, Yilik L, et at. Recent surgical experience in chronic constrictive pericarditis. Tex Heart Inst J 2003;30:27-30.
57. Tirilomis T Unverdorben S, von der Emde J. Pericardectomy for chronic constrictive pericarditis: Risks and outcome. Eur J Cardiothorac Surg 19194;8:487-92.
58. Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: Evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 1999;100:1380-6.
59. Artez HT, Billingham ME, Edwards WD, et al. Myocarditis: The Dallas criteria. Hum Pathol 1987;18:619-24.
60. Baughman KL. Diagnosis of myocarditis: Death of the Dallas criteria. Circulation 2006;113:593-5.
61. Friedrich MG, Sechrem U, Schulz-Menger J, et al; for the International Consensus Group on Cardiovascular MR in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2008 (In press)
62. Dec GW, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates and clinical outcome. New Eng J Med 1985;312:885-90.
63. D'Ambrosio A, Patti D, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: A review. Heart 2001;85:499-504.
64. Wagner FM, Hracka V, Doering V, et al. Bridge to recovery by mechanical ventricular assist (VAD) - a successful therapy for cardiac failure due to acute myocarditis. J Heart Lung Transplant 2006;25:S123.
65. Acker MA. Mechanical circulatory support for patients with acute-fulminant myocarditis. Ann Thorac Surg 2001;71:S73-76.
66. Wagner A, Schulz-Menger J, Dietz R, Friedrich MG. Long-term follow-up of patients with acute myocarditis by magnetic resonance imaging. MAGMA 2003;16:17-20.
67. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147:251-62.
68. Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): Description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm 2008;5:907-25.
69. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systematic review. JAMA 2007;297:2502-14.
70. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
71. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008;117:2608-16.
72. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007;357:2461-71.
73. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol 2007;30(Suppl 1):S23-30.
74. Witte KK, Sasson Z, Persaud JA, Jolliffe R, Wald RW, Parker JD. Biventricular pacing: Impact on exercise-induced increases in mitral insufficiency in patients with chronic heart failure. Can J Cardiol 2008;24:379-84.
75. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: The COMPASS-HF study. J Am Coll Cardiol 2008;51:1073-9.
76. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA 2005;294:1625-33.
77. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
78. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: A subgroup meta-analysis of randomised controlled trials. INDANA Group 1. Lancet 1999;353:793-6.
79. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients aged 80 years or older. N EngI J Med 2008;358:1887-98.
80. Mann JF, Schmeider RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
81. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin, receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008;372:1174-83.
82. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9.
83. Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007;50:32-6.
84. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49:1696-704.
85. Dormandy JA, Charbonnel B, Eckland DJA, et al; on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): A randomized controlled trial. Lancet 2005;366:1279-89.
86. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43.
87. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168:2368-75.
88. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753-62.
89. Palazzuoli A, Silverberg DS, lovine E et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007;154:645:e9-15.
90. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225-7.
91. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-65.
92. Young JB AI, Diaz R, et al. Reduction of events with Darbepoetin alfa in Heart Failure (RED-HF) Trial. J Card Fail 2006;12:S77.
93. Mix TC, Brenner RM, Cooper ME, et al. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005;149:408-13.
94. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006;25:834-8.
95. Metcalf RG, James MJ, Gibson RA, et al. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 2007;85:1222-8.
96. Duda MK, O'shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload,induced cardiac dysfunction. Cardiovasc Res 2009;81:319-27
97. Kris-Etherton P, Daniels SR, Eckel RK et al. Summary of the scientific conference on dietary fatty acids and cardiovascular health: Conference summary from the nutrition committee of the American Heart Association. Circulation 2001;103:1034-9.
98. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999;99:779-05.
99. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002;287:1815-21.
100. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8
101. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: A randomized controlled trial. JAMA 2005;293:2884-91.
102. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: The Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-9.
103. Marchioli R, Barzi F, Bomba E, et al; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell-Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903.
104. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.
105. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet 2008;372:1195-6.
106. Tatarczyk T, Engl J, Ciardi C, et al. Analysis of long-chain omega-3 fatty acid content in fish-oil supplements. Wien Klin Wochenschr 2007;119:417-22.
107. Kris-Etherton PM, Hill AM. n-3 fatty acids: Food or supplements? J Am Diet Assoc 2008;108:1125-30.
108. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorata K. The effects of sirrivastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54.
109. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
110. Krum H, McMurray JJ. Statins and chronic heart failure: Do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.
111. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
112. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
113. Knight BP. Atrial fibrillation in patients with congestive heart failure. Pacing Clin Electrophysiol 2003;26:1620-3.
114. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D.
115. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-5.
116. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
117. Roy D. Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Card Electrophysiol Rev 2003;7:208-10.
118. Januzzi JL Jr, Camargo CA, Anwatuddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
119. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicentre study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33.
120. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
121. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-22.
122. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicentre IMPROVE-CHF study. Circulation 2007;115:3103-10.
123. Januzzi JL, van KR, Lainchbury J, et al. NTproBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7.
124. Januzzi JL, Jr, Sakhuja R, O'Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006;166:315-20.
125. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsaftan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
126. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003;89:879-81.
127. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
128. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
129. Mueller C, Laule-Kilian K, Schindler C, et al. Costeffectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006;166:1081-7.
130. Troughton RW, Frampton CM, Yandle TO, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
131. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicentre Study. J Am Coll Cardiol 2007;49:1733-9.
132. Torre-Amione G, Sestier F, Radovancevic B, Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: Results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004;44:1181-6.
133. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): A placebo-controlled randomised trial. Lancet 2008;371:228-36.
134. McMurray JJ, Teerlink JR, Cotter GD, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure. The VERITAS Randomized Controlled Trials. JAMA 2007;298:2009-19.
135. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure. The SURVIVE randomized trial. JAMA 2007;297:1883-91.
136. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, and oral vasopressin antagonist, in patients hospitalized for heart failure. The EVEREST Clinical, Status Trials. JAMA 2007;297:1332-43.
137. Konstam MA, Gheorgiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST Outoome Trial. JAMA 2007;297:1319-1331.
138. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
139. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. Evian, France, September 6 to 10, 1998 (cosponsored by the World Health Organization). (Version current at April 14, 2000).